Cargando…

High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy

Despite impressive clinical activity in patients with germline BRCA1 and BRCA2 (BRCA1/2) mutant cancers, antitumor responses to poly(ADP-Ribose) polymerase (PARP) inhibitors are variable. We set out to assess the rate of intrapatient radiological differential responses (RDR) to PARP inhibitors, its...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perez-Lopez, Raquel, Roda, Desam, Jimenez, Begona, Brown, Jessica, Mateo, Joaquin, Carreira, Suzanne, Lopez, Juanita, Banerji, Udai, Molife, L. Rhoda, Koh, Dow-Mu, Kaye, Stan B., de Bono, Johann S., Tunariu, Nina, Yap, Timothy A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732817/ https://www.ncbi.nlm.nih.gov/pubmed/29262651 http://dx.doi.org/10.18632/oncotarget.22303

Ejemplares similares

Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy
por: Jannetti, Stephen A., et al.
Publicado: (2020)

Potential biological role of poly (ADP-ribose) polymerase (PARP) in male gametes
por: Agarwal, Ashok, et al.
Publicado: (2009)

Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer
por: Inderjeeth, Andrisha-Jade, et al.
Publicado: (2022)

Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP) – Function in Genome Maintenance and Relevance of Inhibitors for Anti-cancer Therapy
por: Harrision, Daniel, et al.
Publicado: (2020)

The Inhibition and Treatment of Breast Cancer with Poly (ADP-ribose) Polymerase (PARP-1) Inhibitors
por: De Soto, Joseph A., et al.
Publicado: (2006)

Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors
por: Faraoni, Isabella, et al.
Publicado: (2018)

Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1)
por: Zhang, Zhimin, et al.
Publicado: (2020)

Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials
por: Lopez, Juanita, et al.
Publicado: (2015)

Poly(ADP-Ribose) Polymerase 1 (PARP-1) Regulates Ribosomal Biogenesis in Drosophila Nucleoli
por: Boamah, Ernest K., et al.
Publicado: (2012)

Poly(ADP-ribose) polymerase (PARP-1) is not involved in DNA double-strand break recovery
por: Noël, Georges, et al.
Publicado: (2003)

Poly (ADP-ribose) polymerase 3 (PARP3), a potential repressor of telomerase activity
por: Fernández-Marcelo, Tamara, et al.
Publicado: (2014)

PARP2 Is the Predominant Poly(ADP-Ribose) Polymerase in Arabidopsis DNA Damage and Immune Responses
por: Song, Junqi, et al.
Publicado: (2015)

Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?
por: Boussios, Stergios, et al.
Publicado: (2020)

Associations with response to Poly(ADP-ribose) Polymerase (PARP) inhibitors in patients with metastatic breast cancer
por: Desnoyers, A., et al.
Publicado: (2022)

Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate
por: Ström, Cecilia E., et al.
Publicado: (2011)

Deficiency in Poly(ADP-ribose) Polymerase-1 (PARP-1) Accelerates Aging and Spontaneous Carcinogenesis in Mice
por: Piskunova, Tatiana S., et al.
Publicado: (2008)

Active Targeted Nanoparticles for Delivery of Poly(ADP-ribose) Polymerase (PARP) Inhibitors: A Preliminary Review
por: Sargazi, Saman, et al.
Publicado: (2021)

Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents
por: Matanes, Emad, et al.
Publicado: (2021)

Molecular mechanism of poly(ADP-ribosyl)ation by PARP1 and identification of lysine residues as ADP-ribose acceptor sites
por: Altmeyer, Matthias, et al.
Publicado: (2009)

Gemcitabine Induces Poly (ADP-Ribose) Polymerase-1 (PARP-1) Degradation through Autophagy in Pancreatic Cancer
por: Wang, Yufeng, et al.
Publicado: (2014)

Doxorubicin-induced necrosis is mediated by poly-(ADP-ribose) polymerase 1 (PARP1) but is independent of p53
por: Shin, Hyeon-Jun, et al.
Publicado: (2015)

Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review
por: Boussios, Stergios, et al.
Publicado: (2019)

Myeloid malignancies in cancer patients treated with poly(ADP-ribose) polymerase (PARP) inhibitors: a case series
por: Oliveira, Jennifer L., et al.
Publicado: (2022)

New perspectives on the plant PARP family: Arabidopsis PARP3 is inactive, and PARP1 exhibits predominant poly (ADP-ribose) polymerase activity in response to DNA damage
por: Gu, Zongying, et al.
Publicado: (2019)

RNA regulation by Poly(ADP-ribose) polymerases
por: Bock, Florian J., et al.
Publicado: (2015)

Mitotic functions of poly(ADP-ribose) polymerases
por: Slade, Dea
Publicado: (2019)

The Antiviral Activities of Poly-ADP-Ribose Polymerases
por: Malgras, Mathilde, et al.
Publicado: (2021)

Molecular Bases of Catalysis and ADP-Ribose Preference of Human Mn(2+)-Dependent ADP-Ribose/CDP-Alcohol Diphosphatase and Conversion by Mutagenesis to a Preferential Cyclic ADP-Ribose Phosphohydrolase
por: Cabezas, Alicia, et al.
Publicado: (2015)

PARP1-produced poly-ADP-ribose causes the PARP12 translocation to stress granules and impairment of Golgi complex functions
por: Catara, Giuliana, et al.
Publicado: (2017)

Poly(ADP-RIBOSE) polymerase-1 (Parp-1) antagonizes topoisomerase I-dependent recombination stimulation by P53
por: Baumann, Cindy, et al.
Publicado: (2006)

Poly(ADP-Ribose) Polymerase 1 (PARP1) Overexpression in Human Breast Cancer Stem Cells and Resistance to Olaparib
por: Gilabert, Marine, et al.
Publicado: (2014)

Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells
por: Miyasaka, Aki, et al.
Publicado: (2014)

Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic
por: Cerrato, Aniello, et al.
Publicado: (2016)

Nicotinamide, a Poly [ADP-Ribose] Polymerase 1 (PARP-1) Inhibitor, as an Adjunctive Therapy for the Treatment of Alzheimer’s Disease
por: Salech, Felipe, et al.
Publicado: (2020)

Poly (ADP-ribose) polymerase 1 (PARP1) inhibition promotes pulmonary metastasis of osteosarcoma by boosting ezrin phosphorylation
por: Li, Fangfei, et al.
Publicado: (2022)

Beyond PARP1: The Potential of Other Members of the Poly (ADP-Ribose) Polymerase Family in DNA Repair and Cancer Therapeutics
por: Richard, Iain A., et al.
Publicado: (2022)

Identification of poly(ADP-ribose) polymerase 9 (PARP9) as a noncanonical sensor for RNA virus in dendritic cells
por: Xing, Junji, et al.
Publicado: (2021)

Copy number analyses of DNA repair genes reveal the role of poly(ADP-ribose) polymerase (PARP) in tree longevity
por: Aoyagi Blue, Yuta, et al.
Publicado: (2021)

RAD54B mutations enhance the sensitivity of ovarian cancer cells to poly(ADP-ribose) polymerase (PARP) inhibitors
por: Liu, Peng, et al.
Publicado: (2022)

BRCA1/2 Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents
por: Darabi, Sourat, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_avtk40evqjr8hc5vi4o391jdbq